Evaluation of pneumococcal conjugate vaccine (Prevenar) in patients with myeloma and chronic lymphocytic leukaemia
| ISRCTN | ISRCTN21541376 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN21541376 |
| Protocol serial number | 9818P |
| Sponsor | Central Manchester and Manchester Children's Hospital (UK) |
| Funders | Charitable Funds from the Molecular Haematology Fund (9175), Contact: Christine Neild, Charitable Funds Accountant, Wilmslow Park, Hathersage Road, Manchester, M13 0JR |
- Submission date
- 23/11/2005
- Registration date
- 14/03/2006
- Last edited
- 18/10/2017
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof John Liu Yin
Scientific
Scientific
Department of Clinical Haematology
Manchester Royal Infirmary
Oxford Road
Manchester
M13 9WL
United Kingdom
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Interventional non-randomised open label trial |
| Secondary study design | Non randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Evaluation of pneumococcal conjugate vaccine (Prevenar) in patients with myeloma and chronic lymphocytic leukaemia |
| Study objectives | Null hypotheses: 1. The pneumococcal conjugate vaccine (Prevenar) will not provide adequate immunity from pneumococcal disease as measured by antibody levels 2. The pneumococcal conjugate vaccine (Prevenar) does not prime the immune system, resulting in improved responses to subsequent vaccination with the 23-valent polysaccharide vaccine |
| Ethics approval(s) | The proposal was reviewed following submission to Central Office for Research Ethics Committees (COREC) by Salford and Trafford Local Research Ethics Committee on the 8th November 2005. The Research Ethics Committee reference number: 05/Q1404/229. The Committee was content to give a favourable opinion subject to clarification of points raised at the interview. Final approval has now been received dated 28/11/05. |
| Health condition(s) or problem(s) studied | Multiple myeloma and chronic lymphocytic leukaemia |
| Intervention | All study participants will be required to undertake three or four scheduled visits. If the patient is being seen regularly for follow up in the clinic, the trial visits will be scheduled to coincide with these to minimise the number of additional attendances. Visit 1: the potential participants will be informed in detail about the study and given the opportunity to ask any further questions. If they wish to participate they will be formally screened against the exclusion criteria. Provided no contraindications are identified, they will be asked to sign a consent form. Predictable risks and inconveniences will be discussed. A full medical history will be taken, concurrent medication documented and physical examination performed. Details of disease stage will be obtained from the medical records. A case report form has been designed specifically to document all information required and to ensure standardisation. A small blood sample (6 ml) will then be taken for pre-immunisation antibody levels and evaluation of other markers of immune status. Vaccination with the conjugate vaccine will then be administered. Visit 2: this will take place 8-10 weeks following visit 1. The case report form will be completed in a similar manner. A 2 ml blood sample is required for post-vaccination antibody levels. Following this, the second vaccination with the conjugate vaccine will be administered. Visit 3: this will take place 8-10 weeks after the second visit. The case report form will be completed. If the patient has received the 23-valent polysaccharide vaccination in the previous five years, the study will terminate at this point and a blood sample will be taken for antibody response and other markers of immune status (6 ml will be required). Subjects who have not received the 23-valent polysaccharide vaccine in the last five years will be vaccinated with this vaccine on this visit. From the group of patients receiving the vaccine only 2 ml of blood is required for post vaccination antibody levels. Visit 4: only individuals vaccinated at visit 3 will be requested to attend. The visit will take place 6-8 weeks after the third visit. Blood samples will be taken for post immunisation antibody levels and other markers of immune status (6 ml blood). Participants will also be asked if they would be available to attend for one extra visit for an additional blood test only, one week after the second vaccination. This test is optional and supplementary and aims to evaluate how the vaccine is stimulating another aspect of the immune response (cell mediated immunity), which may also be important in providing protection from disease. 15 ml of blood will be needed for this supplementary test. |
| Intervention type | Drug |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Prevenar |
| Primary outcome measure(s) |
To determine whether the pneumococcal conjugate vaccine (Prevenar) can provide immunity from invasive pneumococcal disease in a group of haematology patients at high risk of infective complications |
| Key secondary outcome measure(s) |
1. To determine whether the immune response to the conjugate vaccine (Prevenar) differs between individuals naive to the 23-valent pneumococcal vaccine and those who have received at least one previous dose |
| Completion date | 30/04/2008 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 97 |
| Key inclusion criteria | Patients with multiple myeloma as defined by the demonstration of: 1. Over 10% plasma cells in the bone marrow and at least one of the following: a. Lytic lesions on radiographic X-ray imaging b. A paraprotein in serum or urine 2. Patients with Chronic Lymphocytic Leukemia (CLL) as defined by the demonstration of a clonal population of B-lymphocytes with characteristic immunophenotype (CD5+, CD23+, weak expression of surface Ig (weak SIg), FMC7-negative) in peripheral blood, bone marrow or lymph node biopsy 3. Aged ≥18 years 4. Ability to give written informed consent |
| Key exclusion criteria | 1. Immunoglobulin therapy in the previous four months 2. General contraindications to immunisation as defined in the UK handbook - Immunisation against Infectious Disease 3. Currently receiving treatment prior to planned peripheral blood stem cell or bone marrow transplant 4. Less than six months post peripheral blood stem cell or bone marrow transplant 5. Receiving treatment with high dose steroids (monthly pulsed dexamethasone or >1 mg/kg of prednisolone as a continuous dose) 6. Platelets <30 x 10^9 /l 7. Prior vaccination with Prevenar 8. Prior vaccination with 23-valent pneumococcal vaccine in previous six months 9. Pregnancy 10. Previous splenectomy 11. Other secondary immunodeficiency state e.g. Human Immunodeficiency Virus (HIV) infection |
| Date of first enrolment | 01/12/2005 |
| Date of final enrolment | 30/04/2008 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
Department of Clinical Haematology
Manchester
M13 9WL
United Kingdom
M13 9WL
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
18/10/2017: No publications found, verifying study status with principal investigator.
